Project Grant R35GM153221

Award Date 9/1/24
Completion Date 6/30/29
Dollars Obligated $700K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Clemson, SC 29634, USA
Similar Awards
This Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to expand the metabolic currencies of life for the development of natural product-derived medicines. The $1,111,812 grant, awarded on June 1, 2024, aims to develop methods to improve the efficiency of an unnatural cofactor technology, making it easier to adopt by the bioengineering community. The research also...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $369,178 to North Carolina State University to develop novel chemical labeling strategies for biomolecules using non-aqueous media. The research aims to selectively functionalize hydrophobic, unactivated, and less abundant amino acids on proteins, which was previously challenging in aqueous environments. The long-term...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $371,371 in funding to the University of North Carolina at Chapel Hill to develop new reactions for enabling molecular rigidification. The goal is to create methods to access rigid small and medium-sized ring structures, leveraging sulfone anions as carbene surrogates and stabilizing reactive alkylidene units using palladium...
This National Institutes of Health (NIH) Project Grant award under the Biomedical Research and Research Training program (CFDA 93.859) provides $492,000 to The Trustees of Princeton University to expand the chemical space of microbial and microbiome natural products over a 5-year period from September 1, 2024 to August 31, 2029. The research aims to uncover cryptic natural products from diverse microbial genera, especially those found in the human microbiome, through genome-guided and...
The National Institute of General Medical Sciences (NIGMS) awarded a $393,750 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to The Ohio State University to develop selective cleavable peptide prodrug linkers and multifunctional siderophore-based delivery systems. The goal is to overcome limitations of existing siderophore-antibiotic conjugates and repurpose Gram-positive antibiotics for treating Gram-negative bacterial infections, which are increasingly difficult to...
This $389,995 Project Grant from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports innovative chemical proteomic research at Northwestern University. The primary objectives are to: Establish a chemical proteomic platform to comprehensively map extracellular protein cysteine residues across diverse biological scenarios, including cell activation, genetic manipulation, and chemical treatments. Investigate the...
This $357,125 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research on "Convergent Evolution in Natural Product Biosynthesis." The project aims to establish a new natural product-driven approach to drug lead identification by investigating instances of convergent evolution in natural product biosynthesis, which may indicate molecules of significant biological importance....
The National Institute of General Medical Sciences (NIGMS) awarded a $710,000 Project Grant to The University of Texas at San Antonio under the Biomedical Research and Research Training program (CFDA 93.859). This 5-year grant, running from July 1, 2024 to April 30, 2029, will fund research to develop new sulfinate-based synthetic methodologies for efficiently constructing carbon-heteroatom and carbon-carbon bonds. The research aims to advance organic synthesis and medicinal chemistry by...
The National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) awarded a $317,623 Project Grant (CFDA 93.859 Biomedical Research and Research Training) to the Georgia Tech Research Corporation to develop bioorthogonal chemical methods for site-selective modification of biomolecules. The key objectives are to: 1) create reactive species for identifying small molecule protein targets, 2) develop new proximity labeling tools for interactome studies, and 3) create...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $401,595 to Iowa State University of Science and Technology to conduct research on labdane-related diterpenoid biosynthesis. The research aims to advance the understanding of the enzymes required to produce these natural products, which have potential pharmaceutical and agricultural applications. The award period runs from February...

This $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports two key research focus areas at Clemson University.

The first focus area aims to develop new synthetic methodology to access rare nitrogen-rich heterocyclic compounds, with the goal of expanding the availability of medicinally relevant, densely functionalized heterocycles. This includes accessing and investigating new examples of the diazacyclobutene (DCB) heterocycle, which preliminary data suggests may have anti-parasitic activity. The second focus area will develop new non-microbicidal chemical probes to interrogate polysaccharide metabolism in gut bacteria of the Bacteroides genus, which represents a significant portion of the human microbiome and is associated with various diseases. This work will provide tools to clarify the mechanism of action of the natural product acarbose, which has been shown to disrupt starch utilization systems in these bacteria.

The period of performance for this award is from September 1, 2024 to June 30, 2029.

Generated 4/8/25, 2:55 AM